{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:12Z","timestamp":1793817552899,"version":"4.6.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stroma induces treatment resistance in chronic lymphocytic leukemia (CLL), possibly because of alterations in the BCL-2 family of proteins, which are key regulators of apoptosis. We previously developed BH3 profiling, a functional assay that assesses mitochondrial depolarization in response to BH3-only peptides, to measure \u201capoptotic priming,\u201d the proximity of a cell to the apoptotic threshold. In the present study, we use BH3 profiling to show that CLL cells from the PB are highly primed. Increased priming is associated with improved clinical response and, unexpectedly, with unmutated IGHV status. Coculturing CLL cells in vitro with stroma decreases priming. Using matched PB, BM, and lymph node compartment samples, we found in vivo that BM-derived CLL cells are the least primed. CLL cells cocultured with stroma were treated with the PI3K \u03b4-isoform inhibitor CAL-101 (GS1101). CAL-101 caused CLL cell de-adhesion, leading to increased CLL cell priming. Stimulation of CLL cells with anti-IgM or CXCL12 caused decreased priming that could be reversed by CAL-101. Our results show that inhibition of stromal interactions leading to displacement of CLL cells into the blood by CAL-101 in vivo may increase CLL cell priming, suggesting a mechanism by which agents inducing lymphocyte redistribution might facilitate improved clinical response when used in combina-tion with other therapies.<\/jats:p>","DOI":"10.1182\/blood-2012-02-414060","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:47:37Z","timestamp":1346978857000},"page":"3501-3509","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":118,"title":["Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lannutti","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111808235856000_B1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia.","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111808235856000_B2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia.","volume":"29","author":"Gribben","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808235856000_B3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","article-title":"In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.","volume":"115","author":"Messmer","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111808235856000_B4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111808235856000_B5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/cbt.7.2.5262","article-title":"Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2019111808235856000_B6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111808235856000_B7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"29","key":"2019111808235856000_B8","doi-asserted-by":"crossref","first-page":"12895","DOI":"10.1073\/pnas.0914878107","article-title":"Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.","volume":"107","author":"Ryan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6059","key":"2019111808235856000_B9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"issue":"20","key":"2019111808235856000_B10","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111808235856000_B11","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111808235856000_B12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111808235856000_B13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111808235856000_B14","first-page":"55","article-title":"CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract].","volume":"116","author":"Furman","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"13","key":"2019111808235856000_B15","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111808235856000_B16","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111808235856000_B17","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111808235856000_B18","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111808235856000_B19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4065\/79.3.318","article-title":"Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia\/ small lymphocytic lymphoma.","volume":"79","author":"Ghobrial","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2019111808235856000_B20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1989.tb04290.x","article-title":"Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro.","volume":"71","author":"Collins","year":"1989","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111808235856000_B21","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111808235856000_B22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of Navitoclax in patients with relapsed or refractory disease.","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808235856000_B23","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"3","key":"2019111808235856000_B24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","article-title":"Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.","volume":"101","author":"Lanham","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111808235856000_B25","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood-2007-05-092759","article-title":"Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia.","volume":"111","author":"Roos","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111808235856000_B26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2011.12","article-title":"IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.","volume":"25","author":"Coscia","year":"2011","journal-title":"Leukemia"},{"issue":"9747","key":"2019111808235856000_B27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"2019111808235856000_B28","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2011-07-367417","article-title":"Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.","volume":"119","author":"Paterson","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/17\/3501\/1358549\/zh804312003501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/17\/3501\/1358549\/zh804312003501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:46:58Z","timestamp":1574084818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/17\/3501\/30628\/Decreased-mitochondrial-apoptotic-priming"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,25]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,10,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-02-414060","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,25]]}}}